DDInter1209 DDInter1435
Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Miconazole {u} (Compound) resembles {v} (Compound) Tioconazole
Miconazole {u} (Compound) resembles {v} (Compound) Triclosan
Miconazole {u} (Compound) binds {v} (Gene) KCNMB1
Miconazole {u} (Compound) upregulates {v} (Gene) KIT
Miconazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Miconazole {u} (Compound) downregulates {v} (Gene) STUB1
Miconazole {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Miconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Miconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Miconazole (Compound) resembles Tioconazole (Compound)
Miconazole (Compound) resembles Triclosan (Compound)
Miconazole (Compound) binds KCNMB1 (Gene)
Miconazole (Compound) upregulates KIT (Gene)
Miconazole (Compound) is included by Azoles (Pharmacologic Class)
Miconazole (Compound) downregulates STUB1 (Gene)
Miconazole (Compound) causes Mediastinal disorder (Side Effect)
Miconazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Miconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib